AstraZeneca's Strategic Move: Licensing Eccogene's Oral GLP-1 for $185M upfront
TL;DR Summary
AstraZeneca has acquired an early-stage oral GLP-1 candidate from Eccogene in a deal worth $185 million upfront. AstraZeneca aims to position this oral alternative as a "best in class" option for type 2 diabetes, weight loss, and other indications, despite trailing behind leaders like Novo Nordisk and Eli Lilly in the GLP-1 market.
- AstraZeneca licenses Eccogene's oral GLP-1 for $185M upfront – Endpoints News Endpoints News
- AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug FierceBiotech
- AstraZeneca makes bigger push into weight-loss market with new drug deal The Guardian
- AstraZeneca (AZN) Raises Profit Outlook on Demand for Cancer Drugs Bloomberg
- AstraZeneca raises stakes in obesity drug race with Eccogene deal Reuters
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
13
Time Saved
0 min
vs 1 min read
Condensed
57%
123 → 53 words
Want the full story? Read the original article
Read on Endpoints News